Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in North Carolina: - Atrium Health Stanly/LCI-Albemarle — Albemarle, North Carolina
- Cone Health Cancer Center at Asheboro — Asheboro, North Carolina
- Cone Health MedCenter Asheboro — Asheboro, North Carolina
- Cone Health Cancer Center at Alamance Regional — Burlington, North Carolina
- Duke Cancer Center Cary — Cary, North Carolina
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in North Carolina: - Atrium Health Stanly/LCI-Albemarle — Albemarle, North Carolina
- Cone Health MedCenter Asheboro — Asheboro, North Carolina
- Cone Health Cancer Center at Alamance Regional — Burlington, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Atrium Health Pineville/LCI-Pineville — Charlotte, North Carolina
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…
Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in North Carolina: - Research Site — Charlotte, North Carolina
- Research Site — Durham, North Carolina
- Research Site — Greensboro, North Carolina
- Research Site — Raleigh, North Carolina
- Research Site — Rocky Mount, North Carolina
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in North Carolina: - Levine Cancer Institute ( Site 0083) — Charlotte, North Carolina
- Cape Fear Valley Health System ( Site 0136) — Fayetteville, North Carolina
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in North Carolina: - Clinical Trial Site — Charlotte, North Carolina
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in North Carolina: - Levine Cancer Institute ( Site 0014) — Charlotte, North Carolina
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (H…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07060807
Sites in North Carolina: - Novant Health Cancer Institute ( Site 0019) — Charlotte, North Carolina
- Novant Health Oncology Specialists ( Site 0074) — Winston-Salem, North Carolina
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in North Carolina: - Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in North Carolina: - Atrium Health Wake Forest Baptist - Comprehensive Cancer Center — Winston-Salem, North Carolina
Phase 2 Recruiting NIH
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has sprea…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03606967
Sites in North Carolina: - Wake Forest University at Clemmons — Clemmons, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
Phase 2 Recruiting Academic/Other
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
Phase 2 Recruiting Industry
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extensio…
Sponsor: Dogwood Therapeutics Inc.
NCT ID: NCT06848348
Sites in North Carolina: - Central Recruiting Site — Winston-Salem, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven …
Sponsor: Hoffmann-La Roche
NCT ID: NCT03424005
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in North Carolina: - Carolina BioOncology Institute — Huntersville, North Carolina
Phase 1, Phase 2 Recruiting Industry
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmaco…
Sponsor: Incyclix Bio
NCT ID: NCT05735080
Sites in North Carolina: - Levine Cancer Institute (LCI)- Atrium Health — Charlotte, North Carolina
- Duke Cancer Center/ DUMC — Durham, North Carolina
Phase 2 Recruiting Academic/Other
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The nam…
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04468061
Sites in North Carolina: - The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. …
Sponsor: Mayo Clinic
NCT ID: NCT05557877
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study i…
Sponsor: Nancy Lin, MD
NCT ID: NCT06176261
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 2 Recruiting Academic/Other
This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or with…
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT02422641
Sites in North Carolina: - Comprehensive Cancer Center at Wake Forest University (CCCWFU) — Winston-Salem, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will…
Sponsor: Arvinas Inc.
NCT ID: NCT07749586
Sites in North Carolina: - Clinical Trial Site — Huntersville, North Carolina
Phase 2 Recruiting Academic/Other
This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-re…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT06727773
Sites in North Carolina: - Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
This is a 4-arm, single-center study involving 40 participants. Ten healthy volunteers will be enrolled for system imaging optimization, and thirty (30) patients with previously identified lesions in the breast, liver, or kidney-based on p…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT07225114
Sites in North Carolina: - The University of North Carolina — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
This is a prospective radiation dose-finding, phase 2 expansion study of the Triple Negative (TN) cohort of the multicenter randomized study P-RAD (A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RAD…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT07276880
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina